What:
A prognostic and predictive glycomic marker for Inflammatory Bowel disease (IBD)
Applications:
Prognosis and prediction of need for treatment escalation for newly diagnosed IBD patients. Complementary diagnostic for IBD drugs
Clients:
IBD clinicians, biopharma companies performing clinical trials for IBD
Development Stage:
TRL 6, Designing further clinical studies
What:
Multi-dimensional glycomic marker to measure Chronic inflammation (CI) and Immunofrailty
Applications:
Early detection of CIDs, susceptibility to aIDs, personalization of anti-inflammatory protocols
Clients:
Precision health and wellness companies, regenerative medicine, health-conscious individual clients
Development Stage:
TRL 8, Can be ordered commercially
What:
Glycomic biomarker to identify immunofrail individuals who would be (a) vulnerable to inflammatory storms from COVID-19 and (b) potential non-responders to SARS-Cov-2 vaccines.
Applications:
Selection of patients to clinical trials of SARS-Cov-2 vaccines.
Clients:
Vaccine developers
Development stage:
TRL 5, feasibility study successfully completed. Designing proof of concept.
